Literature DB >> 20679343

Spectroscopic studies of GSK3{beta} phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E.

Arnaud Leroy1, Isabelle Landrieu, Isabelle Huvent, Dominique Legrand, Bernadette Codeville, Jean-Michel Wieruszeski, Guy Lippens.   

Abstract

Alzheimer disease neurons are characterized by extraneuronal plaques formed by aggregated amyloid-β peptide and by intraneuronal tangles composed of fibrillar aggregates of the microtubule-associated Tau protein. Tau is mostly found in a hyperphosphorylated form in these tangles. Glycogen synthase kinase 3β (GSK3β) is a proline-directed kinase generally considered as one of the major players that (hyper)phosphorylates Tau. The kinase phosphorylates mainly (Ser/Thr)-Pro motifs and is believed to require a priming activity by another kinase. Here, we use an in vitro phosphorylation assay and NMR spectroscopy to characterize in a qualitative and quantitative manner the phosphorylation of Tau by GSK3β. We find that three residues can be phosphorylated (Ser-396, Ser-400, and Ser-404) by GSK3β alone, without priming. Ser-404 is essential in this process, as its mutation to Ala prevents all activity of GSK3β. However, priming enhances the catalytic efficacy of the kinase, as initial phosphorylation of Ser-214 by the cAMP-dependent protein kinase (PKA) leads to the rapid modification by GSK3β of four regularly spaced additional sites. Because the regular incorporation of negative charges by GSK3β leads to a potential parallel between phospho-Tau and heparin, we investigated its interaction with the heparin/low density lipoprotein receptor binding domain of human apolipoprotein E. We indeed observed an interaction between the GSK3β-promoted regular phospho-pattern on Tau and the apolipoprotein E fragment but none in the absence of phosphorylation or the presence of an irregular phosphorylation pattern by the prolonged activity of PKA. Apolipoprotein E is therefore able to discriminate and interact with specific phosphorylation patterns of Tau.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20679343      PMCID: PMC2963357          DOI: 10.1074/jbc.M110.149419

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  74 in total

1.  Structure of GSK3beta reveals a primed phosphorylation mechanism.

Authors:  E ter Haar; J T Coll; D A Austen; H M Hsiao; L Swenson; J Jain
Journal:  Nat Struct Biol       Date:  2001-07

2.  Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition.

Authors:  R Dajani; E Fraser; S M Roe; N Young; V Good; T C Dale; L H Pearl
Journal:  Cell       Date:  2001-06-15       Impact factor: 41.582

3.  Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E.

Authors:  R L Raffai; L M Dong; R V Farese; K H Weisgraber
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

4.  Interaction of the N-terminal domain of apolipoprotein E4 with heparin.

Authors:  J Dong; C A Peters-Libeu; K H Weisgraber; B W Segelke; B Rupp; I Capila; M J Hernáiz; L A LeBrun; R J Linhardt
Journal:  Biochemistry       Date:  2001-03-06       Impact factor: 3.162

Review 5.  The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling.

Authors:  C A Grimes; R S Jope
Journal:  Prog Neurobiol       Date:  2001-11       Impact factor: 11.685

6.  Characterization of the heparin binding sites in human apolipoprotein E.

Authors:  Hiroyuki Saito; Padmaja Dhanasekaran; David Nguyen; Faye Baldwin; Karl H Weisgraber; Suzanne Wehrli; Michael C Phillips; Sissel Lund-Katz
Journal:  J Biol Chem       Date:  2003-02-14       Impact factor: 5.157

7.  Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.

Authors:  Yuan Yuan Hu; Shan Shu He; Xiaochuan Wang; Qiu Hong Duan; Inge Grundke-Iqbal; Khalid Iqbal; Jianzhi Wang
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

8.  Increased expression of neuronal apolipoprotein E in human brain with cerebral infarction.

Authors:  Kazuko Aoki; Toshiki Uchihara; Nobuo Sanjo; Ayako Nakamura; Kenji Ikeda; Kuniaki Tsuchiya; Yoshihiro Wakayama
Journal:  Stroke       Date:  2003-03-20       Impact factor: 7.914

9.  Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event.

Authors:  Adam Cole; Sheelagh Frame; Philip Cohen
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

10.  Proline-directed random-coil chemical shift values as a tool for the NMR assignment of the tau phosphorylation sites.

Authors:  Guy Lippens; Jean-Michel Wieruszeski; Arnaud Leroy; Caroline Smet; Alain Sillen; Luc Buée; Isabelle Landrieu
Journal:  Chembiochem       Date:  2004-01-03       Impact factor: 3.164

View more
  27 in total

1.  Expanding the proteome: disordered and alternatively folded proteins.

Authors:  H Jane Dyson
Journal:  Q Rev Biophys       Date:  2011-07-01       Impact factor: 5.318

2.  Nuclear Magnetic Resonance Spectroscopy for the Identification of Multiple Phosphorylations of Intrinsically Disordered Proteins.

Authors:  Clément Danis; Clément Despres; Luiza M Bessa; Idir Malki; Hamida Merzougui; Isabelle Huvent; Haoling Qi; Guy Lippens; François-Xavier Cantrelle; Robert Schneider; Xavier Hanoulle; Caroline Smet-Nocca; Isabelle Landrieu
Journal:  J Vis Exp       Date:  2016-12-27       Impact factor: 1.355

3.  Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology.

Authors:  Shan Liu; Ariel Breitbart; Yanjie Sun; Pankaj D Mehta; Allal Boutajangout; Henrieta Scholtzova; Thomas Wisniewski
Journal:  J Neurochem       Date:  2013-11-06       Impact factor: 5.372

4.  Characterization of Neuronal Tau Protein as a Target of Extracellular Signal-regulated Kinase.

Authors:  Haoling Qi; Sudhakaran Prabakaran; François-Xavier Cantrelle; Béatrice Chambraud; Jeremy Gunawardena; Guy Lippens; Isabelle Landrieu
Journal:  J Biol Chem       Date:  2016-02-08       Impact factor: 5.157

5.  Cell signaling, post-translational protein modifications and NMR spectroscopy.

Authors:  Francois-Xavier Theillet; Caroline Smet-Nocca; Stamatios Liokatis; Rossukon Thongwichian; Jonas Kosten; Mi-Kyung Yoon; Richard W Kriwacki; Isabelle Landrieu; Guy Lippens; Philipp Selenko
Journal:  J Biomol NMR       Date:  2012-09-26       Impact factor: 2.835

6.  Lithium modulates multiple tau kinases with distinct effects in cortical and hippocampal neurons according to concentration ranges.

Authors:  V J De-Paula; O V Forlenza
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-11-09       Impact factor: 3.000

Review 7.  Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer's disease: implications for synaptic dysfunction and neuronal damage.

Authors:  P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2013-06-28

8.  Phosphorylation and O-GlcNAcylation of the PHF-1 Epitope of Tau Protein Induce Local Conformational Changes of the C-Terminus and Modulate Tau Self-Assembly Into Fibrillar Aggregates.

Authors:  François-Xavier Cantrelle; Anne Loyens; Xavier Trivelli; Oliver Reimann; Clément Despres; Neha S Gandhi; Christian P R Hackenberger; Isabelle Landrieu; Caroline Smet-Nocca
Journal:  Front Mol Neurosci       Date:  2021-06-17       Impact factor: 5.639

9.  Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models.

Authors:  Thomas Kramer; Boris Schmidt; Fabio Lo Monte
Journal:  Int J Alzheimers Dis       Date:  2012-07-22

10.  ApoE4 induces Aβ42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice.

Authors:  Ori Liraz; Anat Boehm-Cagan; Daniel M Michaelson
Journal:  Mol Neurodegener       Date:  2013-05-17       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.